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Much research has focused on the opiate prop- 
erties of dynorphin, especially toward differentiat- 
ing its binding to various receptor sub-popula- 
tions. The effects of dynorphin in vitro have clearly 
documented its opiate binding potential. However, 
central administration of dynorphin produces be- 
havioral and electrophysiological effects unlike 
those of classical ~t-, K- or 8-receptor agonists. In 
fact, many of these effects were not reversed by 
even high doses of naloxone. Such findings are 
reminiscent of some effects of ~-endorphin which 
were insensitive to naloxone and could be repro- 
duced with an opiate-inactive fragment, des- 
Tyr-y-endorphin (De Wied et al., 1978). We re- 
cently showed that a number of electrophysiologi- 
cal and behavioral actions of dynorphin could also 
be produced by the fragment des-Tyr-dynorphin 
(Walker et al., 1982). Yet this fragment fails to 
displace tritiated ~t-, ~- or 8-1igands from their 
binding sites in rat brain homogenates. 
One surprising effect of dynorphin was its 
an tagonism of morphine- induced analgesia 
(Friedman et al., 1981). This effect has been dif- 
ficult to explain based on classical opiate-receptor 
models and may be related to its unique non-opiate 
activity. We show that, the opiate-inactive frag- 
ment, des-Tyr-dynorphin, also antagonizes mor- 
phine analgesia, supporting a previous suggestion 
that the in vivo pharmacology of dynorphin has 
both opiate and non-opiate components (Walker 
et al., 1982). 
Stainless steel cannulas were surgically im- 
planted in the left lateral ventrical of 16 male 
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Fig. 1. Effect of intracerebroventricularly administered des- 
Tyr-dynorphin on morphine analgesia. After recording baseline 
tail-flick latencies either des-Tyr-dynorphin or saline was ad- 
ministered to separate groups of rats (n = 16). Analgesia was 
induced over the next 1 h by s.c. injections of morphine sulfate 
(0.75 mg/kg)  at 20 min intervals. Tail-flick testing was con- 
ducted just prior to each injection of morphine. Animals treated 
with des-Tyr-dynorphin exhibited significantly less analgesia 
than those treated with saline. 
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Sprague Dawley rats under deep barbiturate 
anesthesia using methods described elsewhere 
(Walker et al., 1981). After a week of recovery the 
animals were tested for pain sensitivity using the 
tail-flick test of D'Amour and Smith (1941). The 
tail-flick latency of each animal was recorded be- 
fore any treatments, then half the animals received 
des-Tyr-dynorphin (20 ~g) and half received the 
saline vehicle (10 btl) intracerebroventricularly over 
a 1 min period. The tail-flick latency was recorded 
again followed by three injections of morphine 
sulfate (0.75 mg/kg)  s.c. given at 20 rain intervals 
in a cumulative dosing paradigm. The develop- 
ment of analgesia was recorded by tail-flick latency 
prior to each injection of morphine. 
The results, illustrated in fig. 1, show that the 
development of analgesia took place more slowly 
in the presence of des-Tyrosine-dynorphin com- 
pared to the saline vehicle. This effect was con- 
firmed by an analysis of variance (F1, 14 = 8.04; 
P < 0.01). A further analysis of co-variance with 
the baseline trials as the co-variate also indicated a 
significant effect of des-Tyr-dynorphin in reducing 
morphine analgesia (F1, 14 = 7.68; P < 0.01). 
These results add support to the previous find- 
ing that dynorphin antagonizes morphine analge- 
sia. They further suggest that the opiate sequence 
within dynorphin is not necessary for the effect 
and that a second active sequence within the dy- 
norphin molecule is capable of potent effects in 
vivo. The precise location of this proposed active 
site is as yet unknown. Nevertheless, it appears 
that several of the naturally occurring extension of 
enkephalin contain additional active sequences 
having a non-opiate character (De Wied et al., 
1978). 
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